<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01863459</url>
  </required_header>
  <id_info>
    <org_study_id>LDX-COMORB-1</org_study_id>
    <nct_id>NCT01863459</nct_id>
  </id_info>
  <brief_title>Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity</brief_title>
  <official_title>Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate the safety, and efficacy of Lisdexamfetamine dimesylate in the treatment of&#xD;
           outpatients with DSM-IV ADHD with anxiety and depressive disorder comorbidity, as well&#xD;
           as to evaluate the effects on quality of life .&#xD;
&#xD;
        2. To evaluate the efficacy of Lisdexamfetamine dimesylate in the treatment of anxiety and&#xD;
           depressive disorders which commonly occur with ADHD.&#xD;
&#xD;
        3. To examine the potential relationship between telomere length and Adult ADHD with&#xD;
           comorbidity and the potential effect of treatment response.&#xD;
&#xD;
        4. To examine the potential associations with specific genes and Adult ADHD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADHD Rating Scale</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression - Improvement Scale (CGI-I)</measure>
    <time_frame>Change from Week 1 to Week 18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Yale Global Tic Severity Scale (YGTSS)</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Overall Anxiety Severity and Impairment Scale (OASIS)</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Weiss Functional Impairment Rating Scale-Self Report (WFIRS-S)</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barkley Adult ADHD Rating Scale--IV(BAARS-IV)</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revised Padua Inventory</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Panic and Agoraphobia Scale (PAS)</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms (QID-SR-16)</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Sheehan Disability Scale (SDS)</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GAD-7</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Phobia Inventory (SPIN)</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Life Events Questionnaire (LEQ)</measure>
    <time_frame>Visit 2 (Week: Baseline)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Pittsburgh Sleep Quality Index (PSQI)</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Severity (CGI-S)</measure>
    <time_frame>Change from Baseline to Week 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders</condition>
  <arm_group>
    <arm_group_label>Lidexamfetamine Dimesylate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lisdexamfetamine dimesylate (Vyvanse) is a central nervous system (CNS) stimulant, approved for the treatment of ADHD Lisdexamfetamine dimesylate is to be started at a dose of 30 mg/day for one week, increased to 50 mg/day for week 2 and to 70 mg/day for week 3. Doses are increased to the maximally tolerated/efficacious dose. Thirty milligrams of Lisdexamfetamine dimesylate per day, is the minimum dose that must be achieved.&#xD;
Duration of treatment in this arm is 8 weeks; tablet is taken once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be dosed in the same fashion as the active intervention - 3 potential dose levels.&#xD;
Placebo is taken once per day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisdexamfetamine Dimesylate</intervention_name>
    <arm_group_label>Lidexamfetamine Dimesylate</arm_group_label>
    <other_name>Vyvanse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Outpatient men and woman aged 18 to 65 years.&#xD;
&#xD;
          2. Patients with a DSM-IV diagnosis of ADHD according to the MINI-Plus, with an ADHD-RS&#xD;
             score â‰¥ 24 and at least one of the following comorbid psychiatric disorders: SP, PDAG,&#xD;
             OCD, GAD, MDD or Dysthymia.&#xD;
&#xD;
          3. Patients who qualify for comorbid DSM-IV major depressive disorder - current episode,&#xD;
             will be allowed into the study provided that they have a baseline Montgomery Asberg&#xD;
             Depression Rating Scale (MADRS) score of less than or equal to 25.&#xD;
&#xD;
          4. The ability to comprehend and satisfactorily comply with protocol requirements.&#xD;
&#xD;
        6. Written informed consent given prior to entering the baseline period of the study.&#xD;
&#xD;
        7. All women of child bearing potential must have a negative screening visit serum or urine&#xD;
        pregnancy test and be using adequate contraception for the duration of the study. Medically&#xD;
        acceptable forms of contraception include oral contraceptives, injectable or implantable&#xD;
        methods, intrauterine devices or properly used barrier contraception. Additionally, the use&#xD;
        of condoms is suggested as an adjunct to the methods previously addressed to provide&#xD;
        additional protection against accidental pregnancy.&#xD;
&#xD;
        8. Concomitant treatment with selective serotonin reuptake inhibitors (SSRI's), serotonin&#xD;
        noradrenaline reuptake inhibitors (SNRI's), benzodiazepines, beta-blockers, atypical&#xD;
        anti-psychotics, anti-epileptics is allowed, provided the dose has been stable for 8 weeks&#xD;
        prior to study entry. Dose changes of allowed concomitant medication should be avoided&#xD;
        during the treatment phases of the study.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who currently fulfill criteria for a lifetime history of bipolar disorder,&#xD;
             history of drug abuse, a history of schizophrenia or other psychotic disorders,&#xD;
             delirium, dementia and amnesic and other cognitive disorders, or are in a current&#xD;
             agitated state.&#xD;
&#xD;
          2. Patients with a concurrent AXIS-II, cluster A personality disorder or borderline or&#xD;
             antisocial personality disorder.&#xD;
&#xD;
          3. Patients with significant suicidal ideation (MADRS item 10 score &gt; 3) or who have&#xD;
             enacted suicidal behaviours within 6 months prior to intake will be excluded from&#xD;
             study participation and referred for appropriate clinical intervention.&#xD;
&#xD;
          4. Patients receiving current psychotherapy, including cognitive behavioural therapy for&#xD;
             either ADHD or an anxiety or mood disorder, within 4 weeks prior to the baseline&#xD;
             period.&#xD;
&#xD;
          5. Patients who, during the course of the study would be likely to require treatment with&#xD;
             a prohibited concomitant therapy (please refer to Concomitant Medication section&#xD;
             below).&#xD;
&#xD;
          6. Patients who are known to be allergic to amphetamines or components of&#xD;
             Lisdexamfetamine dimesylate, have known hypersensitivity or idiosyncrasy to&#xD;
             Lisdexamfetamine dimesylate or sympathomimetic amines.&#xD;
&#xD;
          7. Patients with a current seizure disorder, organic brain disorder or history of seizure&#xD;
             disorder (except for febrile seizures in childhood).&#xD;
&#xD;
          8. Patients who have thyroid pathology, treatment of which has not been stabilized for at&#xD;
             least 3 months.&#xD;
&#xD;
          9. MAO inhibitors within 3 weeks of the start of the baseline.&#xD;
&#xD;
         10. Current use of bupropion or tri-cyclic antidepressants, with the exception of&#xD;
             clomipramine.&#xD;
&#xD;
         11. Current use of clonidine, modafinil or atomoxetine.&#xD;
&#xD;
         12. Previous intolerance or failure to respond to an adequate trial of Lisdexamfetamine&#xD;
             dimesylate (defined as a minimum of 30mg per day for at least 4 weeks).&#xD;
&#xD;
         13. Current use of any psycho-stimulant, and greater than 2 failed trials using adequate&#xD;
             doses of a methylphenidate-based or amphetamine agent.&#xD;
&#xD;
         14. Pregnant or lactating females or if sexually active and of childbearing potential not&#xD;
             using adequate methods of birth control. If a subject becomes pregnant during the&#xD;
             study she will be discontinued immediately and followed appropriately (at minimum,&#xD;
             until the outcome of the pregnancy is determined).&#xD;
&#xD;
         15. Patients who have a history or evidence of a medical condition that would expose them&#xD;
             to an increase or significant adverse event or interfere with assessments of safety&#xD;
             and efficacy during the course of the trial including: advanced arteriosclerosis,&#xD;
             symptomatic cardiovascular disease, moderate to severe hypertension, or other&#xD;
             pre-existing cardiac abnormalities or other serious cardiac problems.&#xD;
&#xD;
         16. Patients with a history of Glaucoma.&#xD;
&#xD;
         17. Sleep medications during the study period are excluded with the exception of zopiclone&#xD;
             and over-the-counter sleep aids.&#xD;
&#xD;
         18. Patients using any herbal psychoactive treatments, eg; St.John's Wort, Valerian, Kava&#xD;
             Kava, or Chamomile Extract within 14 days prior to randomization.&#xD;
&#xD;
         19. Patients who have received electroconvulsive therapy within the previous 6 months.&#xD;
&#xD;
         20. Patients with any condition or on any therapy that in the investigator's opinion or as&#xD;
             indicated in the Lisdexamfetamine dimesylate product label, that may pose a risk to&#xD;
             the subject or interfere with the study objective.&#xD;
&#xD;
         21. Patients having clinically significant abnormal laboratory or ECG findings not&#xD;
             resolved by the baseline examination.&#xD;
&#xD;
        The exclusion criteria must continue to be satisfied in order for the patient to enter the&#xD;
        randomization phase at the end of the baseline.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Collins, MBChB, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Anxiety, Attention Deficit and Trauma</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 1B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.anxietyaddtreatment.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>May 17, 2013</study_first_submitted>
  <study_first_submitted_qc>May 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2013</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>ADD</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Anxiety Disorders</keyword>
  <keyword>Depression</keyword>
  <keyword>Attention</keyword>
  <keyword>Attention Deficit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

